TRAITEMENT PAR ANTICORPS CHIMERE ANTI-CD20, DE PATIENTS RECEVEURS DE GREFFES DE MOELLE OSSEUSE OU DE CELLULES SOUCHES DE SANG PERIPHERIQUE

• 收藏
• 分享

专利权人:

IDEC PHARMACEUTICALS CORPORATION

发明人:

GRILLO-LOPEZ, ANTONIO J.,LEONARD, JOHN E.

申请号：

CA2350064

公开号：

CA2350064C

申请日:

1999.11.09

申请国别(地区):

CA

年份:

2012

代理人:

摘要：

The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or invitro purging agent, of patients receiving bone marrowor peripheral blood stem cell transplant during treatment of B-cell-relatedmalignancies, e.g., B-cell lymphomas or leukemias, is disclosed.Such purging may enhance engraftment and/or prevent disease relapse in suchpatients.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/